Document is current
Any future updates will be listed below
-
Authors
Myers, Sara P.
Laws, Alison
Dominici, Laura S.
Lagendijk, Mirelle
Grossmith, Samantha
Mittendorf, Elizabeth A.
King, Tari A.
- License Information
-
More Information
Article History
Received: 20 May 2024
Accepted: 4 June 2024
First Online: 19 June 2024
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval for this study was given by the Dana-Farber Cancer Institute research ethics review board (Study 18–214). Participants were all English-speaking adult patients with stage 0-III breast cancer treated between 2002–2012 who participated in the institutional cancer registry and consented in writing to further contact for research purposes.
: EAM reports compensated service on scientific advisory boards for AstraZeneca, BioNTech, Merck, and Moderna; uncompensated service on steering committees for Bristol Myers Squibb and Roche/Genentech; speakers honoraria and travel support from Merck Sharp & Dohme; and institutional research support from Roche/Genentech (via SU2C grant) and Gilead. EAM also reports research funding from Susan Komen for the Cure for which she serves as a Scientific Advisor, and uncompensated participation as a member of the American Society of Clinical Oncology Board of Directors. TAK reports compensated service on advisory board and speakers honoraria from Exact Sciences, and compensated service as faculty for PrecisCa cancer information service. All other authors declare no competing interests.
